Penumbra, Inc. (NYSE:PEN) CFO Sridhar Kosaraju sold 6,026 shares of Penumbra stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $103.83, for a total value of $625,679.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sridhar Kosaraju also recently made the following trade(s):

  • On Wednesday, November 22nd, Sridhar Kosaraju sold 2,600 shares of Penumbra stock. The stock was sold at an average price of $105.99, for a total value of $275,574.00.
  • On Friday, November 24th, Sridhar Kosaraju sold 4,818 shares of Penumbra stock. The stock was sold at an average price of $105.10, for a total value of $506,371.80.
  • On Friday, November 17th, Sridhar Kosaraju sold 4,290 shares of Penumbra stock. The stock was sold at an average price of $103.52, for a total value of $444,100.80.
  • On Monday, November 20th, Sridhar Kosaraju sold 21,956 shares of Penumbra stock. The stock was sold at an average price of $105.27, for a total value of $2,311,308.12.
  • On Wednesday, November 15th, Sridhar Kosaraju sold 10,900 shares of Penumbra stock. The stock was sold at an average price of $105.89, for a total value of $1,154,201.00.

Shares of Penumbra, Inc. (PEN) traded down $0.45 during trading hours on Wednesday, reaching $105.15. The company’s stock had a trading volume of 131,900 shares, compared to its average volume of 192,587. Penumbra, Inc. has a 1-year low of $57.85 and a 1-year high of $116.35.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.07. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The firm’s quarterly revenue was up 24.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) earnings per share. equities research analysts forecast that Penumbra, Inc. will post -0.15 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Penumbra by 10.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after buying an additional 114 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Penumbra in the second quarter worth $213,000. Teacher Retirement System of Texas purchased a new position in shares of Penumbra in the third quarter worth $214,000. Ameritas Investment Partners Inc. raised its stake in shares of Penumbra by 10.8% in the second quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after purchasing an additional 250 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Penumbra in the second quarter worth $252,000. Institutional investors and hedge funds own 71.70% of the company’s stock.

A number of brokerages have recently weighed in on PEN. Canaccord Genuity lifted their price objective on Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets lifted their price target on Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, BidaskClub lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, August 18th.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/29/insider-selling-penumbra-inc-pen-cfo-sells-6026-shares-of-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.